VASCULAR ENDOTHELIAL GROWTH FACTOR VEGF-A AS A MARKER OF ENDOTHELIAL DYSFUNCTION ASSOCIATED WITH SEVERE COVID-19 IN PATIENTS WITH CHRONIC CONCOMITANT PATHOLOGY

SAMIBAEVA Umida Khurshidovna

Journal of Biomedicine and Practice – Biomeditsina va amaliyot jurnali · 2025-yil

Annotatsiya

This study addresses the significance of vascular endothelial growth factor A (VEGF-A) as a potential biomarker of endothelial dysfunction in individuals with severe manifestations of COVID-19, particularly those with pre-existing chronic comorbidities such as diabetes mellitus, hypertension, obesity, and cardiovascular diseases. Endothelial dysfunction has emerged as a key pathological feature in severe SARS-CoV-2 infection, contributing to a range of complications including microthrombosis, exaggerated vascular permeability, and systemic inflammatory responses.The assessment of circulating VEGF-A levels in COVID-19 patients may serve as an early indicator of disease severity and endothelial injury, offering potential utility in risk stratification, prognosis, and therapeutic decision-making. Moreover, VEGF-A could be explored as a target for adjunctive therapy, aiming to mitigate endothelial dysfunction and its clinical consequences in high-risk patient populations.

Maqola ma’lumotlari
MualliflarSAMIBAEVA Umida Khurshidovna
JurnalJournal of Biomedicine and Practice – Biomeditsina va amaliyot jurnali
Nashr sanasi2025-09-06
Jild10
Son3/2
TilIngliz

Kalit so‘zlar

Covid 19, коморбидность, фактор роста эндотелия сосудов (VEGF A), эндотелиальная дисфункция, Covid 19, comorbidity, vascular endothelial growth factor (VEGF A), endothelial dysfunction.

Ilmiy soha

Journal of Biomedicine and Practice – Biomeditsina va amaliyot jurnali jurnalidan boshqa maqolalar

Journal of Biomedicine and Practice – Biomeditsina va amaliyot jurnali — barcha maqolalar